{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T04:18:21Z","timestamp":1794457101971,"version":"4.9.1"},"reference-count":278,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFE0209700"],"award-info":[{"award-number":["2022YFE0209700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772540"],"award-info":[{"award-number":["81772540"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U21A20421"],"award-info":[{"award-number":["U21A20421"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272996"],"award-info":[{"award-number":["82272996"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073882"],"award-info":[{"award-number":["82073882"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073317"],"award-info":[{"award-number":["82073317"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["202201010819"],"award-info":[{"award-number":["202201010819"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["202206010081"],"award-info":[{"award-number":["202206010081"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["2023B03J0029"],"award-info":[{"award-number":["2023B03J0029"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.apsb.2023.12.010","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T22:12:19Z","timestamp":1702678339000},"page":"905-952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Small-molecule agents for cancer immunotherapy"],"prefix":"10.1016","volume":"14","author":[{"given":"Fang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3161-5772","authenticated-orcid":false,"given":"Kai","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7088-1729","authenticated-orcid":false,"given":"Yujue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1589-3791","authenticated-orcid":false,"given":"Can","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0242-9017","authenticated-orcid":false,"given":"Chuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2755-0283","authenticated-orcid":false,"given":"Kenneth Kin Wah","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4528-7960","authenticated-orcid":false,"given":"Chenglai","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianye","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8328-0305","authenticated-orcid":false,"given":"Zhi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6735-1612","authenticated-orcid":false,"given":"Min","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6795-2506","authenticated-orcid":false,"given":"Liwu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2023.12.010_bib1","first-page":"128","article-title":"The diagnosis and treatment of bone sarcoma","volume":"126","author":"Coley","year":"1936","journal-title":"Glasgow Med J"},{"key":"10.1016\/j.apsb.2023.12.010_bib2","article-title":"Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance","volume":"29","author":"O'Malley","year":"1962","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.apsb.2023.12.010_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2023.12.010_bib4","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.apsb.2023.12.010_bib5","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2023.12.010_bib6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2023.12.010_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.apsb.2023.12.010_bib8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41571-022-00601-9","article-title":"Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics","volume":"19","author":"Yamaguchi","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib9","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2020.07.004","article-title":"Clinical challenges of immune checkpoint inhibitors","volume":"38","author":"de Miguel","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2023.12.010_bib10","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1126\/science.1232458","article-title":"Cyclic GMP\u2013AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway","volume":"339","author":"Sun","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.apsb.2023.12.010_bib11","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/j.apsb.2020.03.001","article-title":"Small molecules targeting the innate immune cGAS\u2013STING\u2013TBK1 signaling pathway","volume":"10","author":"Ding","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.12.010_bib12","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.3390\/cancers13112695","article-title":"STING agonists as cancer therapeutics","volume":"13","author":"Amouzegar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.apsb.2023.12.010_bib13","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1016\/j.apsb.2022.11.007","article-title":"Small molecule-based immunomodulators for cancer therapy","volume":"12","author":"Wu","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2023.12.010_bib14","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1078-0432.CCR-21-1963","article-title":"Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced\/metastatic solid tumors or lymphomas","volume":"28","author":"Meric-Bernstam","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib15","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1021\/acs.jmedchem.1c02197","article-title":"Discovery of MK-1454: a potent cyclic dinucleotide stimulator of interferon genes agonist for the treatment of cancer","volume":"65","author":"Chang","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.12.010_bib16","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1158\/1538-7445.AM2020-4522","article-title":"Abstract 4522: potent induction of a tumor-specific immune response by a cyclic dinucleotide STING agonist","volume":"80","author":"Gremel","year":"2020","journal-title":"Am Assoc Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.e14616","article-title":"Preclinical studies of SB 11285, a novel STING agonist for immuno-oncology","volume":"35","author":"Challa","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/2767-9764.CRC-21-0161","article-title":"TAK-676: a novel stimulator of interferon genes (STING) agonist promoting durable IFN-dependent antitumor immunity in preclinical studies","volume":"2","author":"Cunniff","year":"2022","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.apsb.2023.12.010_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba6098","article-title":"An orally available non-nucleotide STING agonist with antitumor activity","volume":"369","author":"Pan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.apsb.2023.12.010_bib20","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1126\/science.abb4255","article-title":"Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic","volume":"369","author":"Chin","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.apsb.2023.12.010_bib21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41586-018-0705-y","article-title":"Design of amidobenzimidazole STING receptor agonists with systemic activity","volume":"564","author":"Ramanjulu","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.12.010_bib22","first-page":"1740","article-title":"E7766, a macrocycle-bridged stimulator of interferon genes (STING) agonist with potent pan-genotypic activity","volume":"16","author":"Kim","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.apsb.2023.12.010_bib23","article-title":"Design of a systemic small molecule clinical STING agonist using physics-based simulations and artificial intelligence","author":"Allen","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.apsb.2023.12.010_bib24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41392-021-00687-0","article-title":"Pattern recognition receptors in health and diseases","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2023.12.010_bib25","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern recognition receptors and inflammation","volume":"140","author":"Takeuchi","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2023.12.010_bib26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nri3446","article-title":"The history of Toll-like receptors-redefining innate immunity","volume":"13","author":"O'Neill","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2023.12.010_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1049340","article-title":"Toll-like receptor-targeted anti-tumor therapies: advances and challenges","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2023.12.010_bib28","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.3390\/pharmaceutics14112285","article-title":"Immunotherapeutic implications of Toll-like receptors activation in tumor microenvironment","volume":"14","author":"Zheng","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2023.12.010_bib29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-021-03363-z","article-title":"A vaccine targeting mutant IDH1 in newly diagnosed glioma","volume":"592","author":"Platten","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.12.010_bib30","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1007\/s00262-021-03024-0","article-title":"Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial","volume":"70","author":"Filaci","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.apsb.2023.12.010_bib31","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1796002","article-title":"Trial watch: experimental TLR7\/TLR8 agonists for oncological indications","volume":"9","author":"Frega","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.apsb.2023.12.010_bib32","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1158\/2159-8290.CD-21-0425","article-title":"Overcoming PD-1 blockade resistance with CpG-A Toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma","volume":"11","author":"Ribas","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2023.12.010_bib33","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1158\/2159-8290.CD-21-1226","article-title":"For Whom the Bell Tolls? A Toll-like receptor 9 agonist's journey from vaccine adjuvant to promising agent in anti-PD-1-resistant melanoma","volume":"11","author":"Sullivan","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2023.12.010_bib34","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1158\/2159-8290.CD-20-1546","article-title":"Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma","volume":"11","author":"Haymaker","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2023.12.010_bib35","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1200\/JCO.2021.39.15_suppl.2614","article-title":"Phase I trial to determine safety and immunogenicity of amplivant, a synthetic toll-like receptor 2 ligand, conjugated to two HPV16 E6 synthetic long peptides","volume":"39","author":"Speetjens","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib36","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/1078-0432.CCR-18-0469","article-title":"Intratumoral G100, a TLR4 agonist, induces antitumor immune responses and tumor regression in patients with Merkel cell carcinoma","volume":"25","author":"Bhatia","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib37","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41585-020-0346-4","article-title":"Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer","volume":"17","author":"van Puffelen","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.apsb.2023.12.010_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001941","article-title":"Rapamycin enhances BCG-specific \u03b3\u03b4 T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study","volume":"9","author":"Ji","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2023.12.010_bib39","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s41573-022-00538-9","article-title":"The expanding role for small molecules in immuno-oncology","volume":"21","author":"Offringa","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2023.12.010_bib40","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/2159-8290.CD-21-1156","article-title":"Characterization of INCB086550: a potent and novel small-molecule PD-L1 inhibitor","volume":"12","author":"Koblish","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2023.12.010_bib41","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3390\/pharmaceutics13050598","article-title":"Metabolism and interspecies variation of IMMH-010, a programmed cell death ligand 1 inhibitor prodrug","volume":"13","author":"Wang","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2023.12.010_bib42","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","article-title":"Control of PD-L1 expression by oncogenic activation of the AKT\u2013mTOR pathway in non-small cell lung cancer","volume":"76","author":"Lastwika","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/path.5280","article-title":"MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells","volume":"249","author":"Stutvoet","year":"2019","journal-title":"J Pathol"},{"key":"10.1016\/j.apsb.2023.12.010_bib44","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jtho.2015.09.010","article-title":"PD-L1 is upregulated by simultaneous amplification of the PD-L1 and JAK2 genes in non-small cell lung cancer","volume":"11","author":"Ikeda","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib45","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.it.2019.02.004","article-title":"Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy","volume":"40","author":"Emran","year":"2019","journal-title":"Trends Immunol"},{"key":"10.1016\/j.apsb.2023.12.010_bib46","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3390\/cancers12020462","article-title":"Decitabine augments chemotherapy-induced PD-L1 upregulation for PD-L1 blockade in colorectal cancer","volume":"12","author":"Huang","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.apsb.2023.12.010_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106245","article-title":"Epigenetically silenced PD-L1 confers drug resistance to anti-PD1 therapy in gastric cardia adenocarcinoma","volume":"82","author":"Zhu","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.apsb.2023.12.010_bib48","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-15-0077-T","article-title":"HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade","volume":"3","author":"Woods","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-020-02653-1","article-title":"Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer","volume":"70","author":"Shi","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.apsb.2023.12.010_bib50","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00262-018-2283-0","article-title":"Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model","volume":"68","author":"Llopiz","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.apsb.2023.12.010_bib51","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/imr.12524","article-title":"New checkpoints in cancer immunotherapy","volume":"276","author":"Ni","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.apsb.2023.12.010_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.07.073","article-title":"Structure and functional binding epitope of V-domain Ig suppressor of T cell activation","volume":"28","author":"Mehta","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2023.12.010_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay0524","article-title":"VISTA is a checkpoint regulator for naive T cell quiescence and peripheral tolerance","volume":"367","author":"ElTanbouly","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.apsb.2023.12.010_bib54","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1084\/jem.20100619","article-title":"VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses","volume":"208","author":"Wang","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.apsb.2023.12.010_bib55","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/s41598-017-01411-1","article-title":"Immune-checkpoint protein VISTA critically regulates the IL-23\/IL-17 inflammatory axis","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2023.12.010_bib56","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1158\/0008-5472.CAN-13-1506","article-title":"VISTA regulates the development of protective antitumor immunity","volume":"74","author":"Le Mercier","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib57","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/cei.13415","article-title":"VISTA: coming of age as a multi-lineage immune checkpoint","volume":"200","author":"ElTanbouly","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.apsb.2023.12.010_bib58","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.3390\/molecules24152804","article-title":"CA-170\u2014a potent small-molecule PD-L1 inhibitor or not?.","volume":"24","author":"Musielak","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2023.12.010_bib59","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s42003-021-02191-1","article-title":"PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy","volume":"4","author":"Sasikumar","year":"2021","journal-title":"Commun Biol"},{"key":"10.1016\/j.apsb.2023.12.010_bib60","doi-asserted-by":"crossref","first-page":"v405","DOI":"10.1093\/annonc\/mdx376.007","article-title":"CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study","volume":"28","author":"Powderly","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib61","first-page":"P714","article-title":"Phase 2 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints VISTA and PD-1, in patients (pts) with advanced solid tumor and Hodgkin lymphoma","volume":"6","author":"Radhakrishnan","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2023.12.010_bib62","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/s42003-021-02381-x","article-title":"Inhibition of lung tumorigenesis by a small molecule CA170 targeting the immune checkpoint protein VISTA","volume":"4","author":"Pan","year":"2021","journal-title":"Commun Biol"},{"key":"10.1016\/j.apsb.2023.12.010_bib63","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev.immunol.24.021605.090737","article-title":"Transforming growth factor-beta regulation of immune responses","volume":"24","author":"Li","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.apsb.2023.12.010_bib64","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","article-title":"TGF\u03b2 biology in cancer progression and immunotherapy","volume":"18","author":"Derynck","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib65","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41568-021-00413-6","article-title":"Overcoming TGF\u03b2-mediated immune evasion in cancer","volume":"22","author":"Tauriello","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2023.12.010_bib66","first-page":"59","article-title":"A small molecule inhibitor of TGF\u03b2 RI kinase potentiates VEGF dependent angiogenesis in vitro","volume":"66","author":"Yingling","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib67","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.1158\/1078-0432.CCR-19-1338","article-title":"Phase II study of the ALK5 inhibitor galunisertib in very low-, low-, and intermediate-risk myelodysplastic syndromes","volume":"25","author":"Santini","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib68","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1002\/cam4.3880","article-title":"Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma","volume":"10","author":"Harding","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.apsb.2023.12.010_bib69","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1007\/s10637-020-00910-9","article-title":"Phase 1b\/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma","volume":"38","author":"Wick","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.apsb.2023.12.010_bib70","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002068","article-title":"Safety and activity of the TGF\u03b2 receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer","volume":"9","author":"Melisi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2023.12.010_bib71","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S1470-2045(22)00446-6","article-title":"Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial","volume":"23","author":"Yamazaki","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib72","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1186\/s12885-023-11153-1","article-title":"A phase Ib\/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer","volume":"23","author":"Nadal","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.apsb.2023.12.010_bib73","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/neuonc\/now009","article-title":"A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma","volume":"18","author":"Brandes","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112354","article-title":"Synthesis and biological evaluation of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor-\u03b2 type 1 receptor inhibitors","volume":"198","author":"Xu","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2023.12.010_bib75","doi-asserted-by":"crossref","first-page":"6666","DOI":"10.1158\/1078-0432.CCR-21-1504","article-title":"First-in-human phase I study of a next-generation, oral, TGF\u03b2 receptor 1 inhibitor, LY3200882, in patients with advanced cancer","volume":"27","author":"Yap","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib76","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41419-023-05630-5","article-title":"Combination treatment of T1-44, a PRMT5 inhibitor with vactosertib, an inhibitor of TGF-\u03b2 signaling, inhibits invasion and prolongs survival in a mouse model of pancreatic tumors","volume":"14","author":"Hong","year":"2023","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2023.12.010_bib77","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1158\/1535-7163.MCT-13-0903","article-title":"EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis","volume":"13","author":"Son","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.apsb.2023.12.010_bib78","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/emmm.201302524","article-title":"Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes","volume":"5","author":"Yoon","year":"2013","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.apsb.2023.12.010_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15430\/JCP.2018.23.1.1","article-title":"Identification of epithelial\u2013mesenchymal transition-related target genes induced by the mutation of smad3 linker phosphorylation","volume":"23","author":"Park","year":"2018","journal-title":"J Cancer Prev"},{"key":"10.1016\/j.apsb.2023.12.010_bib80","first-page":"A82","article-title":"74 Tumor microenvironment based on PD-L1 and CD8 T-cell infiltration correlated with the response of MSS mCRC patients treated vactosertib in combination with pembrolizumab","volume":"9","author":"Kim","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2023.12.010_bib81","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2478\/raon-2022-0012","article-title":"Co-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer","volume":"56","author":"Choi","year":"2022","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib82","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2019-3072","article-title":"Abstract 3072: GFH018, a novel TGF-\u03b2RI inhibitor, for the treatment of advanced solid tumors","volume":"79","author":"Hu","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051034","article-title":"Next generation therapeutics for the treatment of myelofibrosis","volume":"10","author":"Tremblay","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.apsb.2023.12.010_bib84","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2011-09-379214","article-title":"Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling","volume":"119","author":"Hume","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2023.12.010_bib85","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00018-022-04225-1","article-title":"Inhibition of colony stimulating factor-1 receptor (CSF-1R) as a potential therapeutic strategy for neurodegenerative diseases: opportunities and challenges","volume":"79","author":"Han","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.apsb.2023.12.010_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106566","article-title":"Targeting CSF-1R represents an effective strategy in modulating inflammatory diseases","volume":"187","author":"Xiang","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib87","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s40265-019-01210-0","article-title":"Pexidartinib: first approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2023.12.010_bib88","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2023.12.010_bib89","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/neuonc\/nov245","article-title":"Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an ivy foundation early phase clinical trials consortium phase II study","volume":"18","author":"Butowski","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib90","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1158\/1078-0432.CCR-21-1779","article-title":"A phase I study of the combination of pexidartinib and sirolimus to target tumor-associated macrophages in unresectable sarcoma and malignant peripheral nerve sheath tumors","volume":"27","author":"Manji","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib91","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/S1470-2045(20)30496-4","article-title":"Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib92","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","article-title":"Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib93","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13045-018-0695-0","article-title":"Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors","volume":"12","author":"Sun","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib94","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1158\/1078-0432.CCR-21-3009","article-title":"ARRY-382 in combination with pembrolizumab in patients with advanced solid tumors: results from a phase 1b\/2 study","volume":"28","author":"Johnson","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib95","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1158\/1078-0432.CCR-14-1845","article-title":"An open-label, multicenter, phase I\/II study of JNJ-40346527, a CSF-1R inhibitor, in patients with relapsed or refractory hodgkin lymphoma","volume":"21","author":"von Tresckow","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib96","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","article-title":"Harnessing cytokines and chemokines for cancer therapy","volume":"19","author":"Propper","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib97","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.coi.2018.03.004","article-title":"Chemokines and cancer: new immune checkpoints for cancer therapy","volume":"51","author":"Karin","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.apsb.2023.12.010_bib98","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","article-title":"Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial","volume":"17","author":"Nywening","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib99","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s10637-019-00830-3","article-title":"Phase 1b study of a small molecule antagonist of human chemokine (C\u2013C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel\/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma","volume":"38","author":"Noel","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.apsb.2023.12.010_bib100","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2018.36.5_suppl.92","article-title":"Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced\/metastatic pancreatic cancer: correlation with blood monocyte counts","volume":"36","author":"Linehan","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib101","doi-asserted-by":"crossref","first-page":"CT124","DOI":"10.1158\/1538-7445.AM2018-CT124","article-title":"Abstract CT124: a phase Ib\/II study of BMS-813160, a CC chemokine receptor (CCR) 2\/5 dual antagonist, in combination with chemotherapy or nivolumab in patients (pts) with advanced pancreatic or colorectal cancer","volume":"78","author":"Le","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib102","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1172\/JCI82976","article-title":"A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer","volume":"127","author":"Berlato","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2023.12.010_bib103","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071765","article-title":"The CCL5\/CCR5 axis in cancer progression","volume":"12","author":"Aldinucci","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.apsb.2023.12.010_bib104","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.3010","article-title":"Combined PD-1 inhibition (Pembrolizumab) and CCR5 inhibition (Maraviroc) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): first results of the PICCASSO phase I trial","volume":"38","author":"Haag","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib105","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2022.03.017","article-title":"Pembrolizumab and maraviroc in refractory mismatch repair proficient\/microsatellite-stable metastatic colorectal cancer\u2014the PICCASSO phase I trial","volume":"167","author":"Haag","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.apsb.2023.12.010_bib106","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s40425-019-0706-x","article-title":"Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors","volume":"7","author":"Bilusic","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2023.12.010_bib107","first-page":"A239","article-title":"394 Interleukin-8\u2013neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti-PD-(L)1-experienced patients with advanced cancer: initial phase 1 results","volume":"8","author":"Davar","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2023.12.010_bib108","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.574667","article-title":"The role of the CXCL12\/CXCR4\/CXCR7 chemokine axis in cancer","volume":"11","author":"Shi","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2023.12.010_bib109","first-page":"801","article-title":"The CXCL12 (SDF-1)\/CXCR4 chemokine axis: oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy","volume":"16","author":"Zhou","year":"2018","journal-title":"Chin J Nat Med"},{"key":"10.1016\/j.apsb.2023.12.010_bib110","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S1470-2045(18)30147-5","article-title":"Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial","volume":"19","author":"Pernas","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib111","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11523-016-0434-9","article-title":"A randomized, open-label phase 2 study of the CXCR4 inhibitor LY2510924 in combination with sunitinib versus sunitinib alone in patients with metastatic renal cell carcinoma (RCC)","volume":"11","author":"Hainsworth","year":"2016","journal-title":"Target Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib112","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/pancan.2019.0018","article-title":"Safety and pharmacokinetics of CXCR4 peptide antagonist, LY2510924, in combination with durvalumab in advanced refractory solid tumors","volume":"6","author":"O'Hara","year":"2020","journal-title":"J Pancreat Cancer"},{"key":"10.1016\/j.apsb.2023.12.010_bib113","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial","volume":"26","author":"Bockorny","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2023.12.010_bib114","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1152\/physrev.00037.2016","article-title":"Arginase: a multifaceted enzyme important in health and disease","volume":"98","author":"Caldwell","year":"2018","journal-title":"Physiol Rev"},{"key":"10.1016\/j.apsb.2023.12.010_bib115","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41422-020-0379-5","article-title":"Metabolic signaling in T cells","volume":"30","author":"Shyer","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.617699","article-title":"Inhibition of arginase 1 liberates potent T cell immunostimulatory activity of human neutrophil granulocytes","volume":"11","author":"Vonwirth","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2023.12.010_bib117","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/jso.24490","article-title":"Arginine-dual roles as an onconutrient and immunonutrient","volume":"115","author":"Albaugh","year":"2017","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib118","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.yexcr.2018.05.003","article-title":"Arginine inhibits the malignant transformation induced by interferon-gamma through the NF-kappaB-GCN2\/eIF2alpha signaling pathway in mammary epithelial cells in\u00a0vitro and in\u00a0vivo","volume":"368","author":"Ren","year":"2018","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108821","article-title":"Abnormal immune function of MDSC and NK cells from chronic phase CML patients restores with tyrosine kinase inhibitors","volume":"109","author":"Hong","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.apsb.2023.12.010_bib120","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1258504","article-title":"CD13hi neutrophil-like myeloid-derived suppressor cells exert immune suppression through Arginase 1 expression in pancreatic ductal adenocarcinoma","volume":"6","author":"Zhang","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.apsb.2023.12.010_bib121","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1038\/s41467-019-10979-3","article-title":"Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma","volume":"10","author":"Czystowska-Kuzmicz","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2023.12.010_bib122","doi-asserted-by":"crossref","first-page":"v793","DOI":"10.1093\/annonc\/mdz268.100","article-title":"Targeting ARG2 as a novel therapeutic approach for cancer","volume":"30","author":"Grzybowski","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib123","article-title":"Mitochondrial arginase-2 is a cell-autonomous regulator of CD8+ T cell function and antitumor efficacy","volume":"4","author":"Marti i Lindez","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.apsb.2023.12.010_bib124","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.4049\/jimmunol.1301913","article-title":"Repression of arginase-2 expression in dendritic cells by microRNA-155 is critical for promoting T cell proliferation","volume":"193","author":"Dunand-Sauthier","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2023.12.010_bib125","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/cmi.2017.143","article-title":"IDO1 in cancer: a Gemini of immune checkpoints","volume":"15","author":"Zhai","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.apsb.2023.12.010_bib126","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-018-0644-y","article-title":"Targeting the IDO1 pathway in cancer: from bench to bedside","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib127","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.678999","article-title":"IDO1 expression in ovarian cancer induces PD-1 in T cells via aryl hydrocarbon receptor activation","volume":"12","author":"Amobi-McCloud","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2023.12.010_bib128","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bbi.2017.01.022","article-title":"Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4\/PD-L1 inhibition in mouse glioblastoma","volume":"62","author":"Zhai","year":"2017","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.apsb.2023.12.010_bib129","doi-asserted-by":"crossref","first-page":"6650","DOI":"10.1158\/1078-0432.CCR-17-0120","article-title":"Infiltrating T cells increase IDO1 expression in glioblastoma and contribute to decreased patient survival","volume":"23","author":"Zhai","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib130","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1200\/JCO.2018.78.9602","article-title":"Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I\/II trial (ECHO-202\/KEYNOTE-037)","volume":"36","author":"Mitchell","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib131","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1172\/JCI124077","article-title":"IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma","volume":"129","author":"Blair","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2023.12.010_bib132","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002057","article-title":"Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma","volume":"9","author":"Zakharia","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2023.12.010_bib133","article-title":"Prostaglandin E2 and receptors: insight into tumorigenesis, tumor progression, and treatment of hepatocellular carcinoma","volume":"10","author":"Chen","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.apsb.2023.12.010_bib134","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-dependent tumor growth through evasion of immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2023.12.010_bib135","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.18632\/aging.100987","article-title":"A miR-335\/COX-2\/PTEN axis regulates the secretory phenotype of senescent cancer-associated fibroblasts","volume":"8","author":"Kabir","year":"2016","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.apsb.2023.12.010_bib136","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/jid.2008.310","article-title":"Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction","volume":"129","author":"Tjiu","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.apsb.2023.12.010_bib137","doi-asserted-by":"crossref","first-page":"83976","DOI":"10.18632\/oncotarget.6930","article-title":"Tumor-associated macrophages induce vasculogenic mimicry of glioblastoma multiforme through cyclooxygenase-2 activation","volume":"7","author":"Rong","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2023.12.010_bib138","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.7150\/ijbs.15943","article-title":"Cyclooxygenase-2 in tumor-associated macrophages promotes metastatic potential of breast cancer cells through Akt pathway","volume":"12","author":"Gan","year":"2016","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.apsb.2023.12.010_bib139","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1002\/jcp.27411","article-title":"Cyclooxygenase-2 in cancer: a review","volume":"234","author":"Hashemi Goradel","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.apsb.2023.12.010_bib140","doi-asserted-by":"crossref","first-page":"5498","DOI":"10.1182\/blood-2011-07-365825","article-title":"Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells","volume":"118","author":"Obermajer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2023.12.010_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2023.12.010_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2020.10.020","article-title":"Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint blockade","volume":"53","author":"Bonavita","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2023.12.010_bib143","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1001\/jama.2021.2454","article-title":"Effect of celecoxib vs placebo added to standard adjuvant therapy on disease-free survival among patients with stage III colon cancer: the CALGB\/SWOG 80702 (Alliance) randomized clinical trial","volume":"325","author":"Meyerhardt","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.apsb.2023.12.010_bib144","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1001\/jamaoncol.2021.2193","article-title":"Effect of celecoxib vs placebo as adjuvant therapy on disease-free survival among patients with breast cancer: the REACT randomized clinical trial","volume":"7","author":"Coombes","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib145","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","article-title":"Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial","volume":"7","author":"Hu","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.apsb.2023.12.010_bib146","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001\u20132020)","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib147","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bioorg.2017.11.006","article-title":"Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity","volume":"76","author":"Mh","year":"2018","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.apsb.2023.12.010_bib148","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.humimm.2020.12.005","article-title":"Targeting adenosine and regulatory T cells in cancer immunotherapy","volume":"82","author":"Churov","year":"2021","journal-title":"Hum Immunol"},{"key":"10.1016\/j.apsb.2023.12.010_bib149","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.4049\/jimmunol.1900765","article-title":"Adenosine receptor signaling targets both PKA and Epac pathways to polarize dendritic cells to a suppressive phenotype","volume":"203","author":"Kayhan","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2023.12.010_bib150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1012927","article-title":"Immunosuppressive adenosine-targeted biomaterials for emerging cancer immunotherapy","volume":"13","author":"Wei","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2023.12.010_bib151","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1080\/17460441.2018.1534825","article-title":"Targeting adenosine A2A receptor antagonism for treatment of cancer","volume":"13","author":"Congreve","year":"2018","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.apsb.2023.12.010_bib152","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000417","article-title":"Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103+ dendritic cells enhancing anti-tumor immunity","volume":"8","author":"Borodovsky","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2023.12.010_bib153","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/2159-8290.CD-19-1280","article-title":"Lessons from the A2a adenosine receptor antagonist-enabled tumor regression and survival in patients with treatment-refractory renal cell cancer","volume":"10","author":"Sitkovsky","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2023.12.010_bib154","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1158\/1078-0432.CCR-22-0612","article-title":"Phase Ia\/b, open-label, multicenter study of AZD4635 (an adenosine A2a receptor antagonist) as monotherapy or combined with durvalumab, in patients with solid tumors","volume":"28","author":"Lim","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib155","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10637-018-0706-6","article-title":"Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers","volume":"37","author":"Seitz","year":"2019","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.apsb.2023.12.010_bib156","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.5039","article-title":"ARC-6: a phase 1b\/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928)-based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mCRPC)","volume":"39","author":"Subudhi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib157","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2021-CT129","article-title":"Abstract CT129: ARC-3: updated results of etrumadenant (AB928) + modified FOLFOX-6 (mFOLFOX-6) in metastatic colorectal cancer (mCRC) patients","volume":"81","author":"Cecchini","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib158","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1158\/1078-0432.CCR-21-2742","article-title":"Phase I study of taminadenant (PBF509\/NIR178), an adenosine 2A receptor antagonist, with or without spartalizumab (PDR001), in patients with advanced non-small cell lung cancer","volume":"28","author":"Chiappori","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib159","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri1056","article-title":"PI3K in lymphocyte development, differentiation and activation","volume":"3","author":"Okkenhaug","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2023.12.010_bib160","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nri.2016.93","article-title":"PI3K\u03b4 and primary immunodeficiencies","volume":"16","author":"Lucas","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2023.12.010_bib161","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.12.010_bib162","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.immuni.2015.09.001","article-title":"Metabolic reprogramming of immune cells in cancer progression","volume":"43","author":"Biswas","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2023.12.010_bib163","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11971","article-title":"Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer","volume":"7","author":"Hao","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2023.12.010_bib164","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1158\/0008-5472.CAN-11-4141","article-title":"Oncogenic PI3K mutations lead to NF-\u03baB-dependent cytokine expression following growth factor deprivation","volume":"72","author":"Hutti","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib165","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41401-020-00500-8","article-title":"Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity","volume":"41","author":"Sun","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2023.12.010_bib166","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41573-021-00209-1","article-title":"PI3K inhibitors are finally coming of age","volume":"20","author":"Vanhaesebroeck","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2023.12.010_bib167","doi-asserted-by":"crossref","first-page":"283ra51","DOI":"10.1126\/scitranslmed.aaa4442","article-title":"PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer","volume":"7","author":"Bosch","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2023.12.010_bib168","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andre","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2023.12.010_bib169","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1","volume":"32","author":"Andre","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib170","doi-asserted-by":"crossref","first-page":"16589","DOI":"10.1021\/acs.jmedchem.2c01422","article-title":"Discovery of GDC-0077 (inavolisib), a highly selective inhibitor and degrader of mutant PI3K\u03b1","volume":"65","author":"Hanan","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.12.010_bib171","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1158\/1078-0432.CCR-16-2888","article-title":"A first-in-human, phase I, dose-escalation study of TAK-117, a selective PI3K\u03b1 isoform inhibitor, in patients with advanced solid malignancies","volume":"23","author":"Juric","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib172","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/oncolo\/oyac192","article-title":"Randomized phase II trial of sapanisertib\u00a0\u00b1 TAK-117 vs. everolimus in patients with advanced renal cell carcinoma after VEGF-targeted therapy","volume":"27","author":"Choueiri","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.apsb.2023.12.010_bib173","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s40265-014-0285-6","article-title":"Idelalisib: first global approval","volume":"74","author":"Markham","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2023.12.010_bib174","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1056\/NEJMe1400055","article-title":"Idelalisib\u2014a PI3K\u03b4 inhibitor for B-cell cancers","volume":"370","author":"Fruman","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2023.12.010_bib175","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.18.01460","article-title":"Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia","volume":"37","author":"Sharman","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib176","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","article-title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"18","author":"Zelenetz","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib177","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/S2352-3026(17)30019-4","article-title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","volume":"4","author":"Jones","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.apsb.2023.12.010_bib178","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1182\/blood.2019002118","article-title":"Ublituximab and umbralisib in relapsed\/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"134","author":"Lunning","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2023.12.010_bib179","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/S2352-3026(18)30216-3","article-title":"Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial","volume":"6","author":"Nastoupil","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.apsb.2023.12.010_bib180","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/blood-2018-08-867499","article-title":"Parsaclisib, a potent and highly selective PI3K\u03b4 inhibitor, in patients with relapsed or refractory B-cell malignancies","volume":"133","author":"Forero-Torres","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2023.12.010_bib181","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-021-01140-z","article-title":"Phase 1 clinical trial of the PI3K\u03b4 inhibitor YY-20394 in patients with B-cell hematological malignancies","volume":"14","author":"Jiang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib182","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/1078-0432.CCR-22-2939","article-title":"The oral PI3K\u03b4 inhibitor linperlisib for the treatment of relapsed and\/or refractory follicular lymphoma: a phase II, single-arm, open-label clinical trial","volume":"29","author":"Wang","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib183","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119239","article-title":"Tumor-targeted delivery of silibinin and IPI-549 synergistically inhibit breast cancer by remodeling the microenvironment","volume":"581","author":"Jiang","year":"2020","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2023.12.010_bib184","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells","volume":"539","author":"De Henau","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.12.010_bib185","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood.2021011597","article-title":"PI3K\u03b4\/\u03b3 inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity","volume":"139","author":"Funk","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2023.12.010_bib186","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003762","article-title":"PI3K\u03b4\/\u03b3 inhibitor BR101801 extrinsically potentiates effector CD8+ T cell-dependent antitumor immunity and abscopal effect after local irradiation","volume":"10","author":"Yoon","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2023.12.010_bib187","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib188","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib189","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.annonc.2020.12.009","article-title":"Combination treatment of copanlisib and gemcitabine in relapsed\/refractory PTCL (COSMOS): an open-label phase I\/II trial","volume":"32","author":"Yhim","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib190","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1470-2045(21)00145-5","article-title":"Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Matasar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib191","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.annonc.2020.10.596","article-title":"Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial","volume":"32","author":"Dent","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib192","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2023.12.010_bib193","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/1078-0432.CCR-18-1133","article-title":"Targeting cancer cells and tumor microenvironment in preclinical and clinical models of Hodgkin lymphoma using the dual PI3K\u03b4\/\u03b3 inhibitor RP6530","volume":"25","author":"Locatelli","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib194","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(17)30064-5","article-title":"Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"18","author":"Soulieres","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib195","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdw562","article-title":"A randomized adaptive phase II\/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4)","volume":"28","author":"Martin","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib196","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of JAK\u2013STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.apsb.2023.12.010_bib197","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41577-023-00877-7","article-title":"Protein kinases: drug targets for immunological disorders","volume":"23","author":"Castelo-Soccio","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2023.12.010_bib198","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib199","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2023.12.010_bib200","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2023.12.010_bib201","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2023.12.010_bib202","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib203","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.apsb.2023.12.010_bib204","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2023.12.010_bib205","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1200\/JCO.21.02188","article-title":"Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy","volume":"40","author":"Harrison","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib206","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.apsb.2023.12.010_bib207","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib208","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.apsb.2023.12.010_bib209","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naive patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib210","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2023.12.010_bib211","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/2472555220952071","article-title":"Development of high-throughput assays for evaluation of hematopoietic progenitor kinase 1 inhibitors","volume":"26","author":"Lacey","year":"2021","journal-title":"SLAS Discov"},{"key":"10.1016\/j.apsb.2023.12.010_bib212","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114819","article-title":"The development of small-molecule inhibitors targeting HPK1","volume":"244","author":"Zhou","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2023.12.010_bib213","article-title":"Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function","volume":"15","author":"Wang","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2023.12.010_bib214","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/ni1416","article-title":"Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell-mediated immune responses","volume":"8","author":"Shui","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.apsb.2023.12.010_bib215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2020.08.001","article-title":"Hematopoietic progenitor kinase1 (HPK1) mediates T cell dysfunction and is a druggable target for T cell-based immunotherapies","volume":"38","author":"Si","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2023.12.010_bib216","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/jcb.20401","article-title":"Functional interactions of HPK1 with adaptor proteins","volume":"95","author":"Boomer","year":"2005","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.apsb.2023.12.010_bib217","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.celrep.2018.09.012","article-title":"The kinase activity of hematopoietic progenitor kinase 1 is essential for the regulation of T cell function","volume":"25","author":"Hernandez","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2023.12.010_bib218","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/13543776.2021.1924671","article-title":"Inhibitors of immuno-oncology target HPK1\u2014a patent review (2016 to 2020)","volume":"31","author":"Linney","year":"2021","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.apsb.2023.12.010_bib219","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","article-title":"Mechanisms of receptor tyrosine kinase activation in cancer","volume":"17","author":"Du","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2023.12.010_bib220","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-018-0797-x","article-title":"Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges","volume":"17","author":"Butti","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2023.12.010_bib221","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.569082","article-title":"MSP\u2013RON pathway: potential regulator of inflammation and innate immunity","volume":"11","author":"Huang","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2023.12.010_bib222","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nrc3545","article-title":"MSP\u2013RON signalling in cancer: pathogenesis and therapeutic potential","volume":"13","author":"Yao","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2023.12.010_bib223","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041912","article-title":"Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase","volume":"7","author":"Chao","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2023.12.010_bib224","doi-asserted-by":"crossref","first-page":"6105","DOI":"10.1158\/0008-5472.CAN-05-0207","article-title":"A five-amino-acid peptide blocks Met- and Ron-dependent cell migration","volume":"65","author":"Matzke","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib225","doi-asserted-by":"crossref","first-page":"14001","DOI":"10.1074\/jbc.M809320200","article-title":"Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1alpha-mediated invasion of breast carcinoma cells","volume":"284","author":"Thangasamy","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2023.12.010_bib226","doi-asserted-by":"crossref","first-page":"11293","DOI":"10.1074\/jbc.M800154200","article-title":"Smad4-dependent TGF-beta signaling suppresses RON receptor tyrosine kinase-dependent motility and invasion of pancreatic cancer cells","volume":"283","author":"Zhao","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2023.12.010_bib227","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/sj.onc.1206075","article-title":"Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential","volume":"22","author":"Zhou","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2023.12.010_bib228","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/1947601911421924","article-title":"Short-form Ron promotes spontaneous breast cancer metastasis through interaction with phosphoinositide 3-kinase","volume":"2","author":"Liu","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.apsb.2023.12.010_bib229","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1038\/onc.2011.86","article-title":"\u03b2-Catenin is required for Ron receptor-induced mammary tumorigenesis","volume":"30","author":"Wagh","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2023.12.010_bib230","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1158\/0008-5472.CAN-12-2474","article-title":"Myeloid-specific expression of Ron receptor kinase promotes prostate tumor growth","volume":"73","author":"Gurusamy","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib231","doi-asserted-by":"crossref","DOI":"10.4161\/onci.25670","article-title":"RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses","volume":"2","author":"Eyob","year":"2013","journal-title":"OncoImmunology"},{"key":"10.1016\/j.apsb.2023.12.010_bib232","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41416-020-01174-z","article-title":"RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer","volume":"124","author":"Dustin","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2023.12.010_bib233","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1593\/neo.10476","article-title":"Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines","volume":"12","author":"McClaine","year":"2010","journal-title":"Neoplasia"},{"key":"10.1016\/j.apsb.2023.12.010_bib234","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/1078-0432.CCR-14-3283","article-title":"Preclinical efficacy of Ron kinase inhibitors alone and in combination with PI3K inhibitors for treatment of sfRon-expressing breast cancer patient-derived xenografts","volume":"21","author":"Bieniasz","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib235","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1158\/0008-5472.CAN-03-3580","article-title":"Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer","volume":"65","author":"Peace","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib236","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fendo.2019.00089","article-title":"When RON met TAM in mesothelioma: all druggable for one, and one drug for all?","volume":"10","author":"Baird","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.apsb.2023.12.010_bib237","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1158\/0008-5472.CAN-07-6782","article-title":"Identification of a novel recepteur d\u2019origine nantais\/c-met small-molecule kinase inhibitor with antitumor activity in vivo","volume":"68","author":"Zhang","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib238","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1021\/jm801586s","article-title":"Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily","volume":"52","author":"Schroeder","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.12.010_bib239","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1158\/0008-5472.CAN-18-2614","article-title":"Pan-TAM tyrosine kinase inhibitor BMS-777607 enhances anti-PD-1 mAb efficacy in a murine model of triple-negative breast cancer","volume":"79","author":"Kasikara","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib240","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai9338","article-title":"RON kinase: a target for treatment of cancer-induced bone destruction and osteoporosis","volume":"9","author":"Andrade","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2023.12.010_bib241","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1158\/1535-7163.MCT-12-1079","article-title":"Small-molecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents","volume":"12","author":"Sharma","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.apsb.2023.12.010_bib242","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.molonc.2013.12.014","article-title":"Prevention of BMS-777607-induced polyploidy\/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics","volume":"8","author":"Sharma","year":"2014","journal-title":"Mol Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib243","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s10637-018-0588-7","article-title":"A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers","volume":"36","author":"Roohullah","year":"2018","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.apsb.2023.12.010_bib244","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01187","article-title":"Retinoic acid receptor-related orphan receptors: critical roles in tumorigenesis","volume":"9","author":"Fan","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2023.12.010_bib245","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-07203-z","article-title":"Sumoylation of ROR\u03b3t regulates TH17 differentiation and thymocyte development","volume":"9","author":"He","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2023.12.010_bib246","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adc9221","article-title":"Decoupling the role of ROR\u03b3t in the differentiation and effector function of TH17 cells","volume":"8","author":"Zhong","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2023.12.010_bib247","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00101","article-title":"Regulation of CD8+ T cells and antitumor immunity by Notch signaling","volume":"9","author":"Tsukumo","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2023.12.010_bib248","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030551","article-title":"Immune therapy resistance and immune escape of tumors","volume":"13","author":"Seliger","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.apsb.2023.12.010_bib249","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02289-2","article-title":"ROR\u03b3t agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers","volume":"41","author":"Xia","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib250","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1021\/acschembio.0c00941","article-title":"Orthosteric and allosteric dual targeting of the nuclear receptor ROR\u03b3t with a bitopic ligand","volume":"16","author":"Meijer","year":"2021","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.apsb.2023.12.010_bib251","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1158\/1078-0432.CCR-15-2068","article-title":"Regulation of GLI underlies a role for BET bromodomains in pancreatic cancer growth and the tumor microenvironment","volume":"22","author":"Huang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib252","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1182\/bloodadvances.2021004619","article-title":"Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma","volume":"5","author":"Dickinson","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.apsb.2023.12.010_bib253","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41416-020-01180-1","article-title":"A phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma","volume":"124","author":"Shapiro","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2023.12.010_bib254","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13045-016-0362-2","article-title":"Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay","volume":"9","author":"Abruzzese","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib255","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1158\/2159-8290.CD-16-1020","article-title":"Synergistic immunostimulatory effects and therapeutic benefit of combined histone deacetylase and bromodomain inhibition in non-small cell lung cancer","volume":"7","author":"Adeegbe","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2023.12.010_bib256","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1158\/0008-5472.CAN-18-0161","article-title":"NK cells mediate synergistic antitumor effects of combined inhibition of HDAC6 and BET in a SCLC preclinical model","volume":"78","author":"Liu","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2023.12.010_bib257","doi-asserted-by":"crossref","first-page":"10768","DOI":"10.1073\/pnas.1501956112","article-title":"CBP30, a selective CBP\/p300 bromodomain inhibitor, suppresses human Th17 responses","volume":"112","author":"Hammitzsch","year":"2015","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.apsb.2023.12.010_bib258","doi-asserted-by":"crossref","first-page":"13014","DOI":"10.1074\/jbc.M115.708560","article-title":"Regulatory T cell modulation by CBP\/EP300 bromodomain inhibition","volume":"291","author":"Ghosh","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2023.12.010_bib259","doi-asserted-by":"crossref","first-page":"9162","DOI":"10.1021\/acs.jmedchem.7b00796","article-title":"GNE-781, a highly advanced potent and selective bromodomain inhibitor of cyclic adenosine monophosphate response element binding protein, binding protein (CBP)","volume":"60","author":"Romero","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.12.010_bib260","doi-asserted-by":"crossref","first-page":"21847","DOI":"10.1074\/jbc.M501100200","article-title":"High-throughput screening for potent and selective inhibitors of plasmodium falciparum dihydroorotate dehydrogenase","volume":"280","author":"Baldwin","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2023.12.010_bib261","article-title":"Leflunomide for treating rheumatoid arthritis","volume":"2002","author":"Osiri","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.apsb.2023.12.010_bib262","first-page":"1313","article-title":"Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis","volume":"11","author":"Palmer","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.apsb.2023.12.010_bib263","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1038\/s41375-019-0461-5","article-title":"The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies","volume":"33","author":"Christian","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.apsb.2023.12.010_bib264","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2016.08.057","article-title":"Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia","volume":"167","author":"Sykes","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2023.12.010_bib265","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nature09882","article-title":"DHODH modulates transcriptional elongation in the neural crest and melanoma","volume":"471","author":"White","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.12.010_bib266","first-page":"229","article-title":"Discovery of a new pyrimidine synthesis inhibitor eradicating glioblastoma-initiating cells","volume":"22","author":"Echizenya","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.apsb.2023.12.010_bib267","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw7852","article-title":"Identification of DHODH as a therapeutic target in small cell lung cancer","volume":"11","author":"Li","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2023.12.010_bib268","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.153836","article-title":"DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma","volume":"7","author":"Olsen","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.apsb.2023.12.010_bib269","article-title":"A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage","volume":"9","author":"Ladds","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2023.12.010_bib270","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41586-021-03539-7","article-title":"DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer","volume":"593","author":"Mao","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.12.010_bib271","doi-asserted-by":"crossref","DOI":"10.1172\/JCI158661","article-title":"Inhibiting the biogenesis of myeloid-derived suppressor cells enhances immunotherapy efficacy against mammary tumor progression","volume":"132","author":"Colligan","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2023.12.010_bib272","doi-asserted-by":"crossref","first-page":"21453","DOI":"10.1074\/jbc.C200176200","article-title":"The immune modulator FTY720 targets sphingosine 1-phosphate receptors","volume":"277","author":"Brinkmann","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2023.12.010_bib273","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1096\/fj.03-0910fje","article-title":"The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors","volume":"18","author":"Graler","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.apsb.2023.12.010_bib274","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.immuni.2007.11.017","article-title":"S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress","volume":"28","author":"Pham","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2023.12.010_bib275","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.intimp.2008.12.007","article-title":"FTY720 and lung tumor development","volume":"9","author":"Salinas","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.apsb.2023.12.010_bib276","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.cellsig.2010.05.022","article-title":"FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells","volume":"22","author":"Tonelli","year":"2010","journal-title":"Cell Signal"},{"key":"10.1016\/j.apsb.2023.12.010_bib277","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1002\/cam4.1526","article-title":"A comprehensive and perspective view of oncoprotein SET in cancer","volume":"7","author":"Bayarkhangai","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.apsb.2023.12.010_bib278","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383523004793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383523004793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T11:54:31Z","timestamp":1778846071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383523004793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":278,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2211383523004793"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2023.12.010","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small-molecule agents for cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2023.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}